Skip to main content
Evidence Snapshot

Matrix metalloproteinase-9

CHEMBL321 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T19:58:32Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL321
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Matrix metalloproteinase-9 as ChEMBL target CHEMBL321, mapped to UniProt P14780. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Matrix metalloproteinase-9
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL321
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P14780
Matrix metalloproteinase-9
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Matrix metalloproteinase-9 matters

As of 2026-09-13

Matrix metalloproteinase-9 is reviewed as Matrix metalloproteinase-9 (UniProt P14780); Matrix metalloproteinase-9 shows late clinical disease relevance led by breast cancer. 5 more disease programs remain visible in the same review block.; 2 linked drugs keep this evidence frame grounded.; the current evidence base includes 9 approved drugs, 5098 compounds, and 677 assays, with lead potency reaching pChEMBL 11.0.

Disease context
breast cancer

Matrix metalloproteinase-9 shows late clinical disease relevance led by breast cancer. 5 more disease programs remain visible in the same review block. 2 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include MARIMASTAT, REBIMASTAT.

Start review with breast cancer because it currently carries late clinical support. Linked drugs include MARIMASTAT, REBIMASTAT. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Late clinical 2 linked drugs
Activity base
Portfolio and assay base

ChEMBL currently tracks 9 approved drugs, 5098 compounds, and 677 assays for this target. The dominant activity type is IC50. CHEMBL323090 is the current potency anchor at pChEMBL 11.0.

Use CHEMBL323090 as the tractability anchor when discussing potency (pChEMBL 11.0).

Activity source · ChEMBL 36 via Core Engine
9 approved pChEMBL 11.0
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Matrix metalloproteinase-9 matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P14780, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why breast cancer is currently treated as late clinical support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

5098
Total Compounds
677
Total Assays
9
Approved Drugs
IC50: 3927.0, KI: 2119.0, KD: 5.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL323090
 11.0 IC50 —
No preferred name
CHEMBL2064547
 10.5 IC50 —
No preferred name
CHEMBL75094
 10.5 Ki Clinical
No preferred name
CHEMBL75094
 10.3 IC50 Clinical
No preferred name
CHEMBL19611
 10.3 IC50 Clinical

Approved Drugs

Structure Compound First Approval
DACARBAZINE
CHEMBL476
 1975
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T19:58:32Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL321